Ovid Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.108972 million compared to USD 0.011102 million a year ago. Net loss was USD 11.25 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to USD 0.17 a year ago.
For the nine months, revenue was USD 0.250132 million compared to USD 1.46 million a year ago. Net loss was USD 37.02 million compared to USD 42.66 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.61 a year ago. Diluted loss per share from continuing operations was USD 0.52 compared to USD 0.61 a year ago.